{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T14:27:02Z","timestamp":1783348022655,"version":"3.54.6"},"reference-count":96,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T00:00:00Z","timestamp":1778803200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T00:00:00Z","timestamp":1778803200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1245\/s10434-026-19734-7","type":"journal-article","created":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T18:36:58Z","timestamp":1778870218000},"page":"7343-7357","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Biomarker-Driven Management of Nonmetastatic GEJ Adenocarcinoma"],"prefix":"10.1245","volume":"33","author":[{"given":"Hideo","family":"Takahashi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Dehal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haejin","family":"In","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steve","family":"Kwon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariam","family":"Eskander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto J.","family":"Vidri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brett L.","family":"Ecker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin","family":"Ward","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prejesh","family":"Philips","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioannis T.","family":"Konstantinidis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nasreen","family":"Vohra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Kaplan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geoffrey","family":"Nunns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Travis E.","family":"Grotz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richelle","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moshim","family":"Kukar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"The Society of Surgical Oncology (SSO) Gastrointestinal (GI) Disease Site Working Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,15]]},"reference":[{"issue":"3","key":"19734_CR1","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1093\/annonc\/mds244","volume":"24","author":"F Turati","year":"2013","unstructured":"Turati F, Tramacere I, La Vecchia C, Negri E. A meta-analysis of body mass index and esophageal and gastric cardia adenocarcinoma. Ann Oncol. 2013;24(3):609\u201317.","journal-title":"Ann Oncol."},{"issue":"3","key":"19734_CR2","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229\u201363.","journal-title":"CA Cancer J Clin."},{"issue":"4","key":"19734_CR3","doi-asserted-by":"publisher","first-page":"393","DOI":"10.6004\/jnccn.2023.0019","volume":"21","author":"JA Ajani","year":"2023","unstructured":"Ajani JA, D\u2019Amico TA, Bentrem DJ, Cooke D, Corvera C, Das P, et al. Esophageal and esophagogastric junction cancers, version 2.2023, NCCN clinical practice guidelines in oncology. J National Compr Cancer Netw. 2023;21(4):393\u2013422.","journal-title":"J National Compr Cancer Netw"},{"issue":"1","key":"19734_CR4","first-page":"25","volume":"58","author":"JR Siewert","year":"1987","unstructured":"Siewert JR, H\u00f6lscher AH, Becker K, G\u00f6ssner W. Cardia cancer: attempt at a therapeutically relevant classification. Chirurg. 1987;58(1):25\u201332.","journal-title":"Chirurg."},{"issue":"3","key":"19734_CR5","first-page":"173","volume":"9","author":"JR Siewert","year":"1996","unstructured":"Siewert JR, Stein HJ. Carcinoma of the gastroesophageal junction - Classification, pathology and extent of resection. Dis Esophagus. 1996;9(3):173\u201382.","journal-title":"Dis Esophagus."},{"issue":"3","key":"19734_CR6","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1097\/00000658-200009000-00007","volume":"232","author":"J R\u00fcdiger Siewert","year":"2000","unstructured":"R\u00fcdiger Siewert J, Feith M, Werner M, Stein HJ. Adenocarcinoma of the esophagogastric junction: results of surgical therapy based on anatomical\/topographic classification in 1,002 consecutive patients. Ann Surg. 2000;232(3):353\u201361.","journal-title":"Ann Surg."},{"issue":"1","key":"19734_CR7","first-page":"12","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024;74(1):12\u201349.","journal-title":"CA Cancer J Clin."},{"key":"19734_CR8","unstructured":"Comprehensive molecular characterization of gastric adenocarcinoma. Nature. 2014;513(7517):202-9"},{"issue":"35","key":"19734_CR9","doi-asserted-by":"publisher","first-page":"3392","DOI":"10.1200\/JCO.19.01124","volume":"37","author":"F Pietrantonio","year":"2019","unstructured":"Pietrantonio F, Miceli R, Raimondi A, Kim YW, Kang WK, Langley RE, et al. Individual patient data meta-analysis of the value of microsatellite instability as a biomarker in gastric cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2019;37(35):3392\u2013400.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol."},{"issue":"4","key":"19734_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinre.2021.101691","volume":"45","author":"ML Tran-Minh","year":"2021","unstructured":"Tran-Minh ML, Lehmann-Che J, Lambert J, Theou-Anton N, Pot\u00e9 N, Dior M, et al. Prevalence and prognosis of microsatellite instability in oesogastric adenocarcinoma, NORDICAP 16\u201301. Clin Res Hepatol Gastroenterol. 2021;45(4):101691.","journal-title":"Clin Res Hepatol Gastroenterol."},{"issue":"6349","key":"19734_CR11","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1126\/science.aan6733","volume":"357","author":"DT Le","year":"2017","unstructured":"Le DT, Durham JN, Smith KN, Wang H, Bartlett BR, Aulakh LK, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science (New York, NY). 2017;357(6349):409\u201313.","journal-title":"Science (New York, NY)."},{"issue":"13","key":"19734_CR12","doi-asserted-by":"publisher","first-page":"3753","DOI":"10.1158\/1078-0432.CCR-18-4070","volume":"25","author":"L Marcus","year":"2019","unstructured":"Marcus L, Lemery SJ, Keegan P, Pazdur R. FDA approval summary: pembrolizumab for the treatment of microsatellite instability-high solid tumors. Clin Cancer Res Off J Am Assoc Cancer Res. 2019;25(13):3753\u20138.","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res."},{"issue":"10294","key":"19734_CR13","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","volume":"398","author":"YY Janjigian","year":"2021","unstructured":"Janjigian YY, Shitara K, Moehler M, Garrido M, Salman P, Shen L, et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet (London, Engl). 2021;398(10294):27\u201340.","journal-title":"Lancet (London, Engl)."},{"issue":"12","key":"19734_CR14","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.1200\/JCO.22.01351","volume":"41","author":"K Ludford","year":"2023","unstructured":"Ludford K, Ho WJ, Thomas JV, Raghav KPS, Murphy MB, Fleming ND, et al. Neoadjuvant pembrolizumab in localized microsatellite instability high\/deficient mismatch repair solid tumors. J Clin Oncol Official J Am Soc Clin Oncol. 2023;41(12):2181\u201390.","journal-title":"J Clin Oncol Official J Am Soc Clin Oncol."},{"issue":"7","key":"19734_CR15","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1093\/jnci\/djaa217","volume":"113","author":"M Bilusic","year":"2021","unstructured":"Bilusic M, Gulley JL. Neoadjuvant immunotherapy: an evolving paradigm shift? J Natl Cancer Inst. 2021;113(7):799\u2013800.","journal-title":"J Natl Cancer Inst."},{"issue":"14","key":"19734_CR16","doi-asserted-by":"publisher","first-page":"11849","DOI":"10.3390\/ijms241411849","volume":"24","author":"E Boydell","year":"2023","unstructured":"Boydell E, Sandoval JL, Michielin O, Obeid M, Addeo A, Friedlaender A. Neoadjuvant immunotherapy: a promising new standard of care. Int J Mol Sci. 2023;24(14):11849.","journal-title":"Int J Mol Sci"},{"issue":"7","key":"19734_CR17","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1200\/JCO.22.02331","volume":"41","author":"MA Shah","year":"2023","unstructured":"Shah MA, Kennedy EB, Alarcon-Rozas AE, Alcindor T, Bartley AN, Malowany AB, et al. Immunotherapy and targeted therapy for advanced gastroesophageal cancer: ASCO guideline. J Clin Oncol Off J Am Soc Clin Oncol. 2023;41(7):1470\u201391.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol."},{"issue":"5","key":"19734_CR18","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.0013","volume":"4","author":"CS Fuchs","year":"2018","unstructured":"Fuchs CS, Doi T, Jang RW, Muro K, Satoh T, Machado M, et al. Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: phase 2 clinical KEYNOTE-059 trial. JAMA Oncol. 2018;4(5):e180013.","journal-title":"JAMA Oncol."},{"issue":"10142","key":"19734_CR19","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/S0140-6736(18)31257-1","volume":"392","author":"K Shitara","year":"2018","unstructured":"Shitara K, \u00d6zg\u00fcro\u011flu M, Bang YJ, Di Bartolomeo M, Mandal\u00e0 M, Ryu MH, et al. Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial. Lancet (London, Engl). 2018;392(10142):123\u201333.","journal-title":"Lancet (London, Engl)."},{"issue":"10","key":"19734_CR20","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1001\/jamaoncol.2020.3370","volume":"6","author":"K Shitara","year":"2020","unstructured":"Shitara K, Van Cutsem E, Bang YJ, Fuchs C, Wyrwicz L, Lee KW, et al. Efficacy and safety of pembrolizumab or pembrolizumab plus chemotherapy vs chemotherapy alone for patients with first-line, advanced gastric cancer: the KEYNOTE-062 phase 3 randomized clinical trial. JAMA Oncol. 2020;6(10):1571\u201380.","journal-title":"JAMA Oncol."},{"issue":"6","key":"19734_CR21","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1001\/jamaoncol.2021.0275","volume":"7","author":"J Chao","year":"2021","unstructured":"Chao J, Fuchs CS, Shitara K, Tabernero J, Muro K, Van Cutsem E, et al. Assessment of pembrolizumab therapy for the treatment of microsatellite instability-high gastric or gastroesophageal junction cancer among patients in the KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 clinical trials. JAMA Oncol. 2021;7(6):895\u2013902.","journal-title":"JAMA Oncol."},{"issue":"2","key":"19734_CR22","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1200\/JCO.22.00686","volume":"41","author":"T Andr\u00e9","year":"2023","unstructured":"Andr\u00e9 T, Tougeron D, Piessen G, de la Fouchardi\u00e8re C, Louvet C, Adenis A, et al. Neoadjuvant nivolumab plus ipilimumab and adjuvant nivolumab in localized deficient mismatch repair\/microsatellite instability-high gastric or esophagogastric junction adenocarcinoma: the GERCOR NEONIPIGA phase II study. J Clin Oncol Off J Am Soc Clin Oncol. 2023;41(2):255\u201365.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol."},{"issue":"11","key":"19734_CR23","doi-asserted-by":"publisher","first-page":"2839","DOI":"10.3390\/cancers13112839","volume":"13","author":"A Raimondi","year":"2021","unstructured":"Raimondi A, Palermo F, Prisciandaro M, Aglietta M, Antonuzzo L, Aprile G, et al. TremelImumab and durvalumab combination for the non-operative management (NOM) of microsatellite instability (MSI)-high resectable gastric or gastroesophageal junction cancer: the multicentre, single-arm, multi-cohort, phase II INFINITY study. Cancers. 2021;13(11):2839.","journal-title":"Cancers"},{"key":"19734_CR24","doi-asserted-by":"crossref","unstructured":"Pietrantonio F, Raimondi A, Lonardi S, Murgioni S, Cardellino GG, Tamberi S, et al. INFINITY: a multicentre, single-arm, multi-cohort, phase II trial of tremelimumab and durvalumab as neoadjuvant treatment of patients with microsatellite instability-high (MSI) resectable gastric or gastroesophageal junction adenocarcinoma (GAC\/GEJAC). J Clin Oncol. 2023;41(4_suppl):358-.","DOI":"10.1200\/JCO.2023.41.4_suppl.358"},{"issue":"3","key":"19734_CR25","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.annonc.2024.11.016","volume":"36","author":"A Raimondi","year":"2025","unstructured":"Raimondi A, Lonardi S, Murgioni S, Cardellino GG, Tamberi S, Strippoli A, et al. Tremelimumab and durvalumab as neoadjuvant or non-operative management strategy of patients with microsatellite instability-high resectable gastric or gastroesophageal junction adenocarcinoma: the\u00a0INFINITY study by GONO. Ann Oncol. 2025;36(3):285\u201396.","journal-title":"Ann Oncol."},{"issue":"4","key":"19734_CR26","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1200\/JCO.23.00975","volume":"42","author":"S Lorenzen","year":"2024","unstructured":"Lorenzen S, G\u00f6tze TO, Thuss-Patience P, Biebl M, Homann N, Schenk M, et al. Perioperative atezolizumab plus fluorouracil, leucovorin, oxaliplatin, and docetaxel for resectable esophagogastric cancer: interim results from the randomized, multicenter, phase II\/III DANTE\/IKF-s633 trial. J Clin Oncol Off J Am Soc Clin Oncol. 2024;42(4):410\u201320.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol."},{"issue":"2","key":"19734_CR27","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/S1470-2045(23)00541-7","volume":"25","author":"K Shitara","year":"2024","unstructured":"Shitara K, Rha SY, Wyrwicz LS, Oshima T, Karaseva N, Osipov M, et al. Neoadjuvant and adjuvant pembrolizumab plus chemotherapy in locally advanced gastric or gastro-oesophageal cancer (KEYNOTE-585): an interim analysis of the multicentre, double-blind, randomised phase 3 study. Lancet Oncol. 2024;25(2):212\u201324.","journal-title":"Lancet Oncol."},{"issue":"3","key":"19734_CR28","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1056\/NEJMoa2503701","volume":"393","author":"YY Janjigian","year":"2025","unstructured":"Janjigian YY, Al-Batran SE, Wainberg ZA, Muro K, Molena D, Van Cutsem E, et al. Perioperative durvalumab in gastric and gastroesophageal junction cancer. New Engl J Med. 2025;393(3):217\u201330.","journal-title":"New Engl J Med"},{"issue":"20","key":"19734_CR29","doi-asserted-by":"publisher","first-page":"2465","DOI":"10.2217\/fon-2022-0093","volume":"18","author":"YY Janjigian","year":"2022","unstructured":"Janjigian YY, Van Cutsem E, Muro K, Wainberg Z, Al-Batran SE, Hyung WJ, et al. MATTERHORN: phase III study of durvalumab plus FLOT chemotherapy in resectable gastric\/gastroesophageal junction cancer. Future Oncol. 2022;18(20):2465\u201373.","journal-title":"Future Oncol."},{"key":"19734_CR30","doi-asserted-by":"publisher","first-page":"S1315","DOI":"10.1016\/j.annonc.2023.10.074","volume":"34","author":"Y Janjigian","year":"2023","unstructured":"Janjigian Y, Al-Batran S, Wainberg Z, Van Cutsem E, Molena D, Muro K, et al. LBA73 Pathological complete response (pCR) to durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) in resectable gastric and gastroesophageal junction cancer (GC\/GEJC): interim results of the global, phase III MATTERHORN study. Ann Oncol. 2023;34:S1315\u20136.","journal-title":"Ann Oncol."},{"issue":"2","key":"19734_CR31","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1093\/annonc\/mdi064","volume":"16","author":"M Tanner","year":"2005","unstructured":"Tanner M, Hollm\u00e9n M, Junttila TT, Kapanen AI, Tommola S, Soini Y, et al. Amplification of HER-2 in gastric carcinoma: association with opoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Ann Oncol. 2005;16(2):273\u20138.","journal-title":"Ann Oncol."},{"issue":"9","key":"19734_CR32","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1093\/annonc\/mdn169","volume":"19","author":"C Gravalos","year":"2008","unstructured":"Gravalos C, Jimeno A. HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. Ann Oncol. 2008;19(9):1523\u20139.","journal-title":"Ann Oncol."},{"issue":"9742","key":"19734_CR33","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","volume":"376","author":"YJ Bang","year":"2010","unstructured":"Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet (London, Engl). 2010;376(9742):687\u201397.","journal-title":"Lancet (London, Engl)."},{"issue":"7890","key":"19734_CR34","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1038\/s41586-021-04161-3","volume":"600","author":"YY Janjigian","year":"2021","unstructured":"Janjigian YY, Kawazoe A, Ya\u00f1ez P, Li N, Lonardi S, Kolesnik O, et al. The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer. Nature. 2021;600(7890):727\u201330.","journal-title":"Nature."},{"issue":"10418","key":"19734_CR35","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1016\/S0140-6736(23)02033-0","volume":"402","author":"YY Janjigian","year":"2023","unstructured":"Janjigian YY, Kawazoe A, Bai Y, Xu J, Lonardi S, Metges JP, et al. Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial. Lancet (London, Engl). 2023;402(10418):2197\u2013208.","journal-title":"Lancet (London, Engl)."},{"issue":"2","key":"19734_CR36","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/S1470-2045(21)00718-X","volume":"23","author":"HP Safran","year":"2022","unstructured":"Safran HP, Winter K, Ilson DH, Wigle D, DiPetrillo T, Haddock MG, et al. Trastuzumab with trimodality treatment for oesophageal adenocarcinoma with HER2 overexpression (NRG Oncology\/RTOG 1010): a multicentre, randomised, phase 3 trial. Lancet Oncol. 2022;23(2):259\u201369.","journal-title":"Lancet Oncol."},{"key":"19734_CR37","doi-asserted-by":"crossref","unstructured":"Hofheinz RD, Haag GM, Ettrich TJ, Borchert K, Kretzschmar A, Teschendorf C, et al. Perioperative trastuzumab and pertuzumab in combination with FLOT versus FLOT alone for HER2-positive resectable esophagogastric adenocarcinoma: final results of the PETRARCA multicenter randomized phase II trial of the AIO. J Clin Oncol. 2020;38(15_suppl):4502-.","DOI":"10.1200\/JCO.2020.38.15_suppl.4502"},{"issue":"10","key":"19734_CR38","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1016\/S1470-2045(18)30481-9","volume":"19","author":"J Tabernero","year":"2018","unstructured":"Tabernero J, Hoff PM, Shen L, Ohtsu A, Shah MA, Cheng K, et al. Pertuzumab plus trastuzumab and chemotherapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (JACOB): final analysis of a double-blind, randomised, placebo-controlled phase 3 study. Lancet Oncol. 2018;19(10):1372\u201384.","journal-title":"Lancet Oncol."},{"issue":"1","key":"19734_CR39","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1186\/s12885-019-5675-4","volume":"19","author":"AD Wagner","year":"2019","unstructured":"Wagner AD, Grabsch HI, Mauer M, Marreaud S, Caballero C, Thuss-Patience P, et al. EORTC-1203-GITCG - the \u201cINNOVATION\u201d-trial: effect of chemotherapy alone versus chemotherapy plus trastuzumab, versus chemotherapy plus trastuzumab plus pertuzumab, in the perioperative treatment of HER2 positive, gastric and gastroesophageal junction adenocarcinoma on pathologic response rate: a randomized phase II-intergroup trial of the EORTC-Gastrointestinal Tract Cancer Group, Korean Cancer Study Group and Dutch Upper GI-Cancer group. BMC Cancer. 2019;19(1):494.","journal-title":"BMC Cancer."},{"key":"19734_CR40","doi-asserted-by":"crossref","unstructured":"Wagner AD, Grabsch HI, Mauer ME, Lorenzen S, Bouche O, Thuss-Patience PC, et al. EORTC-1203 GITC \"INNOVATION\": integration of trastuzumab (T), with or without pertuzumab (P), into perioperative chemotherapy of HER-2 positive stomach cancer: overall survival results. J Clin Oncol. 2025;43(4_suppl):LBA331-LBA.","DOI":"10.1200\/JCO.2025.43.4_suppl.LBA331"},{"issue":"4","key":"19734_CR41","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1056\/NEJMoa2409408","volume":"392","author":"J Hoeppner","year":"2025","unstructured":"Hoeppner J, Brunner T, Schmoor C, Bronsert P, Kulemann B, Claus R, et al. Perioperative chemotherapy or preoperative chemoradiotherapy in esophageal cancer. N Engl J Med. 2025;392(4):323\u201335.","journal-title":"N Engl J Med."},{"issue":"25","key":"19734_CR42","doi-asserted-by":"publisher","first-page":"2419","DOI":"10.1056\/NEJMoa2004413","volume":"382","author":"K Shitara","year":"2020","unstructured":"Shitara K, Bang YJ, Iwasa S, Sugimoto N, Ryu MH, Sakai D, et al. Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer. New Engl J Med. 2020;382(25):2419\u201330.","journal-title":"New Engl J Med."},{"key":"19734_CR43","doi-asserted-by":"crossref","unstructured":"Elimova E, Ajani JA, Burris III HA, Denlinger CS, Iqbal S, Kang Y-K, et al. Zanidatamab+ chemotherapy as first-line treatment for HER2-expressing metastatic gastroesophageal adenocarcinoma (mGEA). Am Soc Clin Oncol; 2023.","DOI":"10.1200\/JCO.2023.41.4_suppl.347"},{"issue":"29","key":"19734_CR44","doi-asserted-by":"publisher","first-page":"3255","DOI":"10.2217\/fon-2022-0595","volume":"18","author":"J Tabernero","year":"2022","unstructured":"Tabernero J, Shen L, Elimova E, Ku G, Liu T, Shitara K, et al. HERIZON-GEA-01: zanidatamab + chemo \u00b1 tislelizumab for 1L treatment of HER2-positive gastroesophageal adenocarcinoma. Future Oncol. 2022;18(29):3255\u201366.","journal-title":"Future Oncol."},{"key":"19734_CR45","doi-asserted-by":"crossref","unstructured":"Takahari D, Kawazoe A, Machida N, Minashi K, Yamagata Y, Hara H, et al. Phase 2 study of trastuzumab deruxtecan as neoadjuvant treatment for HER2-positive gastric and gastroesophageal junction adenocarcinoma (EPOC2003). J Clin Oncol. 2024;42(3_suppl):309-.","DOI":"10.1200\/JCO.2024.42.3_suppl.309"},{"issue":"12","key":"19734_CR46","doi-asserted-by":"publisher","first-page":"4197","DOI":"10.1038\/s41591-025-03979-y","volume":"31","author":"A Stein","year":"2025","unstructured":"Stein A, Goekkurt E, Al-Batran S-E, Moosmann N, Ettrich TJ, Goetze T, et al. Perioperative pembrolizumab, trastuzumab and FLOT in HER2-positive localized esophagogastric adenocarcinoma: a phase 2 trial. Nat Med. 2025;31(12):4197\u2013204.","journal-title":"Nat Med."},{"issue":"1","key":"19734_CR47","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa055531","volume":"355","author":"D Cunningham","year":"2006","unstructured":"Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355(1):11\u201320.","journal-title":"N Engl J Med."},{"issue":"13","key":"19734_CR48","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.1200\/JCO.2010.33.0597","volume":"29","author":"M Ychou","year":"2011","unstructured":"Ychou M, Boige V, Pignon JP, Conroy T, Bouch\u00e9 O, Lebreton G, et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol Off J Am Soc Clin Oncol. 2011;29(13):1715\u201321.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol."},{"issue":"9","key":"19734_CR49","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1016\/S1470-2045(15)00040-6","volume":"16","author":"J Shapiro","year":"2015","unstructured":"Shapiro J, van Lanschot JJB, Hulshof M, van Hagen P, van Berge Henegouwen MI, Wijnhoven BPL, et al. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial. Lancet Oncol. 2015;16(9):1090\u20138.","journal-title":"Lancet Oncol."},{"issue":"12","key":"19734_CR50","doi-asserted-by":"publisher","first-page":"1990","DOI":"10.1002\/cncr.32066","volume":"125","author":"M Greally","year":"2019","unstructured":"Greally M, Agarwal R, Ilson DH. Optimal management of gastroesophageal junction cancer. Cancer. 2019;125(12):1990\u20132001.","journal-title":"Cancer."},{"issue":"28","key":"19734_CR51","doi-asserted-by":"publisher","first-page":"4535","DOI":"10.1200\/JCO.22.02279","volume":"41","author":"M Faron","year":"2023","unstructured":"Faron M, Cheugoua-Zanetsie M, Tierney J, Thirion P, Nankivell M, Winter K, et al. Individual participant data network meta-analysis of neoadjuvant chemotherapy or chemoradiotherapy in esophageal or gastroesophageal junction carcinoma. J Clin Oncol Off J Am Soc Clin Oncol. 2023;41(28):4535\u201347.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol."},{"issue":"22","key":"19734_CR52","doi-asserted-by":"publisher","first-page":"2074","DOI":"10.1056\/NEJMoa1112088","volume":"366","author":"P Van Hagen","year":"2012","unstructured":"Van Hagen P, Hulshof MCCM, Van Lanschot JJB, Steyerberg EW, Henegouwen MVB, Wijnhoven BPL, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. New Engl J Med. 2012;366(22):2074\u201384.","journal-title":"New Engl J Med"},{"issue":"25","key":"19734_CR53","doi-asserted-by":"publisher","first-page":"2803","DOI":"10.1200\/JCO.20.03611","volume":"39","author":"KA Goodman","year":"2021","unstructured":"Goodman KA, Ou FS, Hall NC, Bekaii-Saab T, Fruth B, Twohy E, et al. Randomized phase II study of PET response-adapted combined modality therapy for esophageal cancer: mature results of the CALGB 80803 (Alliance) trial. J Clin Oncol Off J Am Soc Clin Oncol. 2021;39(25):2803\u201315.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol."},{"issue":"13","key":"19734_CR54","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1056\/NEJMoa2032125","volume":"384","author":"RJ Kelly","year":"2021","unstructured":"Kelly RJ, Ajani JA, Kuzdzal J, Zander T, Van Cutsem E, Piessen G, et al. Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer. N Engl J Med. 2021;384(13):1191\u2013203.","journal-title":"N Engl J Med."},{"issue":"12","key":"19734_CR55","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1016\/S1470-2045(16)30531-9","volume":"17","author":"SE Al-Batran","year":"2016","unstructured":"Al-Batran SE, Hofheinz RD, Pauligk C, Kopp HG, Haag GM, Luley KB, et al. Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2\/3 trial. Lancet Oncol. 2016;17(12):1697\u2013708.","journal-title":"Lancet Oncol."},{"issue":"3","key":"19734_CR56","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/S1470-2045(14)70028-2","volume":"15","author":"T Conroy","year":"2014","unstructured":"Conroy T, Galais MP, Raoul JL, Bouch\u00e9 O, Gourgou-Bourgade S, Douillard JY, et al. Definitive chemoradiotherapy with FOLFOX versus fluorouracil and cisplatin in patients with oesophageal cancer (PRODIGE5\/ACCORD17): final results of a randomised, phase 2\/3 trial. Lancet Oncol. 2014;15(3):305\u201314.","journal-title":"Lancet Oncol."},{"issue":"7","key":"19734_CR57","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1200\/JCO.2007.12.9593","volume":"26","author":"J Tepper","year":"2008","unstructured":"Tepper J, Krasna MJ, Niedzwiecki D, Hollis D, Reed CE, Goldberg R, et al. Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. J Clin Oncol Off J Am Soc Clin Oncol. 2008;26(7):1086\u201392.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol."},{"key":"19734_CR58","unstructured":"Network NCC. Esophageal and Esophagogastric Junction Cancers Version 4.2023. 2024:https:\/\/www.nccn.org\/login?ReturnURL=https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/esophageal.pdf."},{"issue":"24","key":"19734_CR59","doi-asserted-by":"publisher","first-page":"3953","DOI":"10.1200\/JCO.2006.06.4840","volume":"24","author":"JA Ajani","year":"2006","unstructured":"Ajani JA, Winter K, Okawara GS, Donohue JH, Pisters PW, Crane CH, et al. Phase II trial of preoperative chemoradiation in patients with localized gastric adenocarcinoma (RTOG 9904): quality of combined modality therapy and pathologic response. J Clin Oncol Off J Am Soc Clin Oncol. 2006;24(24):3953\u20138.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol."},{"key":"19734_CR60","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.ejca.2016.11.031","volume":"74","author":"S Mukherjee","year":"2017","unstructured":"Mukherjee S, Hurt CN, Gwynne S, Sebag-Montefiore D, Radhakrishna G, Gollins S, et al. NEOSCOPE: a randomised phase II study of induction chemotherapy followed by oxaliplatin\/capecitabine or carboplatin\/paclitaxel based pre-operative chemoradiation for resectable oesophageal adenocarcinoma. Eur J Cancer. 2017;74:38\u201346.","journal-title":"Eur J Cancer."},{"key":"19734_CR61","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1186\/s12885-016-2335-9","volume":"16","author":"M Messager","year":"2016","unstructured":"Messager M, Mirabel X, Tresch E, Paumier A, Vendrely V, Dahan L, et al. Preoperative chemoradiation with paclitaxel-carboplatin or with fluorouracil-oxaliplatin-folinic acid (FOLFOX) for resectable esophageal and junctional cancer: the PROTECT-1402, randomized phase 2 trial. BMC Cancer. 2016;16:318.","journal-title":"BMC Cancer."},{"key":"19734_CR62","unstructured":"Adenis A, Sourd SL, Mirabel X, Paumier A, Bogart E, Vendrely V, et al. Preoperative chemoradiation (CRT) with carboplatin (CBP)\/paclitaxel (PCL) (CP) or with 5-fluorouracil (FU)\/oxaliplatin (OX) (Fx) for esophageal or junctional cancer: A randomized phase 2 trial. J Clin Oncol. 2022;40(16_suppl):4015-."},{"issue":"8","key":"19734_CR63","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1111\/dote.12432","volume":"29","author":"G Lin","year":"2016","unstructured":"Lin G, Han SY, Xu YP, Mao WM. Increasing the interval between neoadjuvant chemoradiotherapy and surgery in esophageal cancer: a meta-analysis of published studies. Dis Esophagus. 2016;29(8):1107\u201314.","journal-title":"Dis Esophagus."},{"key":"19734_CR64","first-page":"11","volume":"59","author":"Q Qin","year":"2018","unstructured":"Qin Q, Xu H, Liu J, Zhang C, Xu L, Di X, et al. Does timing of esophagectomy following neoadjuvant chemoradiation affect outcomes? A meta-analysis Int J Surg. 2018;59:11\u20138.","journal-title":"A meta-analysis. Int J Surg."},{"issue":"1","key":"19734_CR65","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/dote\/dox116","volume":"31","author":"H Tie","year":"2018","unstructured":"Tie H, He F, Shen J, Zhang B, Ye M, Chen B, et al. Prolonged interval between neoadjuvant chemoradiotherapy and esophagectomy does not benefit the outcome in esophageal cancer: a systematic review and meta-analysis. Dis Esophagus. 2018;31(1):1\u20139.","journal-title":"Dis Esophagus."},{"issue":"6","key":"19734_CR66","doi-asserted-by":"publisher","first-page":"687","DOI":"10.4251\/wjgo.v12.i6.687","volume":"12","author":"QX Shang","year":"2020","unstructured":"Shang QX, Yang YS, Gu YM, Zeng XX, Zhang HL, Hu WP, et al. Timing of surgery after neoadjuvant chemoradiotherapy affects oncologic outcomes in patients with esophageal cancer. World J Gastrointest Oncol. 2020;12(6):687\u201398.","journal-title":"World J Gastrointest Oncol."},{"issue":"10184","key":"19734_CR67","doi-asserted-by":"publisher","first-page":"1948","DOI":"10.1016\/S0140-6736(18)32557-1","volume":"393","author":"SE Al-Batran","year":"2019","unstructured":"Al-Batran SE, Homann N, Pauligk C, Goetze TO, Meiler J, Kasper S, et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2\/3 trial. Lancet (London, Engl). 2019;393(10184):1948\u201357.","journal-title":"Lancet (London, Engl)."},{"key":"19734_CR68","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1186\/s12885-016-2564-y","volume":"16","author":"J Hoeppner","year":"2016","unstructured":"Hoeppner J, Lordick F, Brunner T, Glatz T, Bronsert P, R\u00f6thling N, et al. ESOPEC: prospective randomized controlled multicenter phase III trial comparing perioperative chemotherapy (FLOT protocol) to neoadjuvant chemoradiation (CROSS protocol) in patients with adenocarcinoma of the esophagus (NCT02509286). BMC Cancer. 2016;16:503.","journal-title":"BMC Cancer."},{"issue":"11","key":"19734_CR69","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1016\/S2468-1253(23)00243-1","volume":"8","author":"JV Reynolds","year":"2023","unstructured":"Reynolds JV, Preston SR, O\u2019Neill B, Lowery MA, Baeksgaard L, Crosby T, et al. Trimodality therapy versus perioperative chemotherapy in the management of locally advanced adenocarcinoma of the oesophagus and oesophagogastric junction (Neo-AEGIS): an open-label, randomised, phase 3 trial. Lancet Gastroenterol Hepatol. 2023;8(11):1015\u201327.","journal-title":"Lancet Gastroenterol Hepatol."},{"issue":"6","key":"19734_CR70","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1200\/JCO.2008.17.0506","volume":"27","author":"M Stahl","year":"2009","unstructured":"Stahl M, Walz MK, Stuschke M, Lehmann N, Meyer HJ, Riera-Knorrenschild J, et al. Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction. J Clin Oncol Official J Am Soc Clin Oncol. 2009;27(6):851\u20136.","journal-title":"J Clin Oncol Official J Am Soc Clin Oncol."},{"issue":"3","key":"19734_CR71","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1016\/j.ejca.2010.09.009","volume":"47","author":"BH Burmeister","year":"2011","unstructured":"Burmeister BH, Thomas JM, Burmeister EA, Walpole ET, Harvey JA, Thomson DB, et al. Is concurrent radiation therapy required in patients receiving preoperative chemotherapy for adenocarcinoma of the oesophagus? A randomised phase II trial. Eur J Cancer. 2011;47(3):354\u201360.","journal-title":"Eur J Cancer."},{"issue":"4","key":"19734_CR72","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1093\/annonc\/mdw010","volume":"27","author":"F Klevebro","year":"2016","unstructured":"Klevebro F, Von D\u00f6beln GA, Wang N, Johnsen G, Jacobsen AB, Friesland S, Hatlevoll I, Glenjen NI, Lind P, Tsai JA, Lundell L. A randomized clinical trial of neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the oesophagus or gastro-oesophageal junction. Ann Oncol. 2016;27(4):660\u20137.","journal-title":"Ann Oncol"},{"issue":"19","key":"19734_CR73","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1056\/NEJMoa2405195","volume":"391","author":"T Leong","year":"2024","unstructured":"Leong T, Smithers BM, Michael M, Haustermans K, Wong R, Gebski V, et al. Preoperative chemoradiotherapy for resectable gastric cancer. New Engl J Med. 2024;391(19):1810\u201321.","journal-title":"New Engl J Med."},{"issue":"1","key":"19734_CR74","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1186\/s12885-020-07388-x","volume":"20","author":"S Lorenzen","year":"2020","unstructured":"Lorenzen S, Biederst\u00e4dt A, Ronellenfitsch U, Rei\u00dffelder C, M\u00f6nig S, Wenz F, et al. RACE-trial: neoadjuvant radiochemotherapy versus chemotherapy for patients with locally advanced, potentially resectable adenocarcinoma of the gastroesophageal junction - A randomized phase III joint study of the AIO, ARO and DGAV. BMC Cancer. 2020;20(1):886.","journal-title":"BMC Cancer."},{"key":"19734_CR75","doi-asserted-by":"crossref","unstructured":"Kelly RJ, Ajani JA, Kuzdzal J, Zander T, Cutsem EV, Piessen G, et al. Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer (EC\/GEJC) following neoadjuvant chemoradiotherapy (CRT): first results of overall survival (OS) from CheckMate 577. J Clin Oncol. 2025;43(16_suppl):4000-.","DOI":"10.1200\/JCO.2025.43.16_suppl.4000"},{"issue":"1","key":"19734_CR76","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.athoracsur.2024.02.021","volume":"118","author":"CN Fick","year":"2024","unstructured":"Fick CN, Dunne EG, Sihag S, Molena D, Cytryn SL, Janjigian YY, Wu AJ, Worrell SG, Hofstetter WL, Jones DR, Gray KD. Immunotherapy for resectable locally advanced esophageal carcinoma. Ann Thorac Surg. 2024;118(1):130\u201340.","journal-title":"Ann Thorac Surg"},{"issue":"12","key":"19734_CR77","doi-asserted-by":"publisher","first-page":"3351","DOI":"10.1158\/1078-0432.CCR-20-4443","volume":"27","author":"T van den Ende","year":"2021","unstructured":"van den Ende T, de Clercq NC, van Berge Henegouwen MI, Gisbertz SS, Geijsen ED, Verhoeven RHA, et al. Neoadjuvant chemoradiotherapy combined with atezolizumab for resectable esophageal adenocarcinoma: a single-arm phase II feasibility trial (PERFECT). Clin Cancer Res Off J Am Assoc Cancer Res. 2021;27(12):3351\u20139.","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res."},{"issue":"11","key":"19734_CR78","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.39778","volume":"5","author":"F Ge","year":"2022","unstructured":"Ge F, Huo Z, Cai X, Hu Q, Chen W, Lin G, et al. Evaluation of clinical and safety outcomes of neoadjuvant immunotherapy combined with chemotherapy for patients with resectable esophageal cancer: a systematic review and meta-analysis. JAMA Netw Open. 2022;5(11):e2239778.","journal-title":"JAMA Netw Open."},{"issue":"14","key":"19734_CR79","doi-asserted-by":"publisher","first-page":"3021","DOI":"10.1158\/1078-0432.CCR-22-0413","volume":"28","author":"M Zhu","year":"2022","unstructured":"Zhu M, Chen C, Foster NR, Hartley C, Mounajjed T, Salomao MA, et al. Pembrolizumab in Combination with neoadjuvant chemoradiotherapy for patients with resectable adenocarcinoma of the gastroesophageal junction. Clin Cancer Res Off J Am Assoc Cancer Res. 2022;28(14):3021\u201331.","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res."},{"issue":"12","key":"19734_CR80","doi-asserted-by":"publisher","first-page":"1702","DOI":"10.1001\/jamaoncol.2023.4423","volume":"9","author":"GA Manji","year":"2023","unstructured":"Manji GA, Lee S, Del Portillo A, May M, Ana SS, Alouani E, et al. Chemotherapy and immune checkpoint blockade for gastric and gastroesophageal junction adenocarcinoma. JAMA Oncol. 2023;9(12):1702\u20137.","journal-title":"JAMA Oncol."},{"issue":"10","key":"19734_CR81","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.2217\/fon-2020-0969","volume":"17","author":"MA Shah","year":"2021","unstructured":"Shah MA, Bennouna J, Doi T, Shen L, Kato K, Adenis A, et al. KEYNOTE-975 study design: a phase III study of definitive chemoradiotherapy plus pembrolizumab in patients with esophageal carcinoma. Future Oncol. 2021;17(10):1143\u201353.","journal-title":"Future Oncol."},{"issue":"2","key":"19734_CR82","doi-asserted-by":"publisher","first-page":"286","DOI":"10.3390\/cancers16020286","volume":"16","author":"C Dennehy","year":"2024","unstructured":"Dennehy C, Khan AF, Zaidi AH, Lam VK. The evolving landscape of neoadjuvant immunotherapy in gastroesophageal cancer. Cancers. 2024;16(2):286.","journal-title":"Cancers"},{"issue":"10","key":"19734_CR83","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1056\/NEJMoa010187","volume":"345","author":"JS Macdonald","year":"2001","unstructured":"Macdonald JS, Smalley SR, Benedetti J, Hundahl SA, Estes NC, Stemmermann GN, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med. 2001;345(10):725\u201330.","journal-title":"N Engl J Med."},{"issue":"19","key":"19734_CR84","doi-asserted-by":"publisher","first-page":"2327","DOI":"10.1200\/JCO.2011.36.7136","volume":"30","author":"SR Smalley","year":"2012","unstructured":"Smalley SR, Benedetti JK, Haller DG, Hundahl SA, Estes NC, Ajani JA, et al. Updated analysis of SWOG-directed intergroup study 0116: a phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection. J Clin Oncol Off J Am Soc Clin Oncol. 2012;30(19):2327\u201333.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol."},{"issue":"5","key":"19734_CR85","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1016\/S1470-2045(18)30132-3","volume":"19","author":"A Cats","year":"2018","unstructured":"Cats A, Jansen EPM, van Grieken NCT, Sikorska K, Lind P, Nordsmark M, et al. Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): an international, open-label, randomised phase 3 trial. Lancet Oncol. 2018;19(5):616\u201328.","journal-title":"Lancet Oncol."},{"issue":"33","key":"19734_CR86","doi-asserted-by":"publisher","first-page":"4387","DOI":"10.1200\/JCO.2011.36.5908","volume":"29","author":"M Sasako","year":"2011","unstructured":"Sasako M, Sakuramoto S, Katai H, Kinoshita T, Furukawa H, Yamaguchi T, et al. Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2011;29(33):4387\u201393.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol."},{"issue":"12","key":"19734_CR87","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1016\/S1470-2045(14)70473-5","volume":"15","author":"SH Noh","year":"2014","unstructured":"Noh SH, Park SR, Yang HK, Chung HC, Chung IJ, Kim SW, et al. Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial. Lancet Oncol. 2014;15(12):1389\u201396.","journal-title":"Lancet Oncol."},{"key":"19734_CR88","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.ejca.2017.04.027","volume":"81","author":"M Stahl","year":"2017","unstructured":"Stahl M, Walz MK, Riera-Knorrenschild J, Stuschke M, Sandermann A, Bitzer M, et al. Preoperative chemotherapy versus chemoradiotherapy in locally advanced adenocarcinomas of the oesophagogastric junction (POET): Long-term results of a controlled randomised trial. Eur J Cancer. 2017;81:183\u201390.","journal-title":"Eur J Cancer."},{"key":"19734_CR89","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.ejca.2017.01.032","volume":"76","author":"F Petrelli","year":"2017","unstructured":"Petrelli F, Tomasello G, Barni S. Surrogate end-points for overall survival in 22 neoadjuvant trials of gastro-oesophageal cancers. Eur J Cancer. 2017;76:8\u201316.","journal-title":"Eur J Cancer."},{"issue":"23","key":"19734_CR90","doi-asserted-by":"publisher","first-page":"7624","DOI":"10.1158\/1078-0432.CCR-08-1547","volume":"14","author":"U Sahin","year":"2008","unstructured":"Sahin U, Koslowski M, Dhaene K, Usener D, Brandenburg G, Seitz G, et al. Claudin-18 splice variant 2 is a pan-cancer target suitable for therapeutic antibody development. Clin Cancer Res. 2008;14(23):7624\u201334.","journal-title":"Clin Cancer Res."},{"issue":"8","key":"19734_CR91","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1038\/s41591-023-02465-7","volume":"29","author":"MA Shah","year":"2023","unstructured":"Shah MA, Shitara K, Ajani JA, Bang YJ, Enzinger P, Ilson D, et al. Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial. Nat Med. 2023;29(8):2133\u201341.","journal-title":"Nat. Med."},{"issue":"10389","key":"19734_CR92","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1016\/S0140-6736(23)00620-7","volume":"401","author":"K Shitara","year":"2023","unstructured":"Shitara K, Lordick F, Bang YJ, Enzinger P, Ilson D, Shah MA, et al. Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial. The Lancet. 2023;401(10389):1655\u201368.","journal-title":"The Lancet"},{"issue":"2","key":"19734_CR93","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1007\/s10120-014-0360-4","volume":"18","author":"AK Nagatsuma","year":"2015","unstructured":"Nagatsuma AK, Aizawa M, Kuwata T, Doi T, Ohtsu A, Fujii H, et al. Expression profiles of HER2, EGFR, MET and FGFR2 in a large cohort of patients with gastric adenocarcinoma. Gastric Cancer. 2015;18(2):227\u201338.","journal-title":"Gastric Cancer"},{"key":"19734_CR94","doi-asserted-by":"publisher","DOI":"10.1200\/PO-24-00710","volume":"9","author":"SY Rha","year":"2025","unstructured":"Rha SY, Zhang Y, Elme A, Pazo Cid R, Alacacioglu A, Ziogas DC, et al. Prevalence of FGFR2b protein overexpression in advanced gastric cancers during prescreening for the phase III FORTITUDE-101 trial. JCO Precis Oncol. 2025;9:e2400710.","journal-title":"JCO Precis Oncol."},{"issue":"11","key":"19734_CR95","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1016\/S1470-2045(22)00603-9","volume":"23","author":"ZA Wainberg","year":"2022","unstructured":"Wainberg ZA, Enzinger PC, Kang YK, Qin S, Yamaguchi K, Kim IH, et al. Bemarituzumab in patients with FGFR2b-selected gastric or gastro-oesophageal junction adenocarcinoma (FIGHT): a randomised, double-blind, placebo-controlled, phase 2 study. Lancet Oncol. 2022;23(11):1430\u201340.","journal-title":"Lancet Oncol."},{"issue":"3","key":"19734_CR96","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1007\/s10120-024-01466-w","volume":"27","author":"ZA Wainberg","year":"2024","unstructured":"Wainberg ZA, Kang YK, Lee KW, Qin S, Yamaguchi K, Kim IH, et al. Bemarituzumab as first-line treatment for locally advanced or metastatic gastric\/gastroesophageal junction adenocarcinoma: final analysis of the randomized phase 2 FIGHT trial. Gastric Cancer. 2024;27(3):558\u201370.","journal-title":"Gastric Cancer."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-026-19734-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-026-19734-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-026-19734-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T14:08:27Z","timestamp":1783346907000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-026-19734-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,15]]},"references-count":96,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["19734"],"URL":"https:\/\/doi.org\/10.1245\/s10434-026-19734-7","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,15]]},"assertion":[{"value":"6 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}